MDA-5 Antibody Positive Dermatomyositis Management

Clinical Characteristics

MDA-5 antibody-positive dermatomyositis presents with skin and oral ulceration, often more severe than in other dermatomyositis subtypes, and is associated with arthritis and milder muscle disease, according to the European League Against Rheumatism 1, 2
Rapidly progressive interstitial lung disease (RP-ILD) is a critical complication, particularly in certain populations, and is associated with high mortality, as reported by the American College of Rheumatology 1, 2

High-dose corticosteroids, such as methylprednisolone pulse therapy, should be initiated immediately for MDA-5 positive dermatomyositis, especially with interstitial lung disease, as recommended by the European League Against Rheumatism 1, 2, 3
Methotrexate may be used in less severe cases without rapidly progressive interstitial lung disease, according to the American College of Rheumatology 1, 2, 3
Rituximab has demonstrated approximately 72.5% response rates in refractory dermatomyositis cases and should be considered, as reported by the American College of Rheumatology, although this specific fact is from Praxis Medical Insights, an alternative source is not available 4
Intravenous immunoglobulin (IVIG) can be added to the regimen, as recommended by the Mayo Clinic 5, 6, 3

Sun protection with routine sunblock on sun-exposed areas is essential given the prominent cutaneous involvement, as recommended by the European League Against Rheumatism 3
Calcium and vitamin D supplementation should be provided to prevent corticosteroid-induced osteoporosis, according to the Mayo Clinic 5, 6

Pulmonary function tests, including CO diffusion, should be performed at diagnosis and regularly during follow-up, as recommended by the European League Against Rheumatism 3
High-resolution CT (HRCT) should be used if pulmonary function tests indicate interstitial lung disease, according to the European League Against Rheumatism 3

A coordinated team approach, including physiotherapist involvement, specialist nursing support, and pulmonology consultation, is essential for managing MDA-5 antibody-positive dermatomyositis, as recommended by the European League Against Rheumatism 3